Celgene Earnings Preview: Analysts Expect Falling Revenue, Rising EPS Over Last Quarter

Celgene CELG announces its next round of earnings this Thursday, July 28, 2011. Get the latest predictions in Benzinga's essential guide to the company's second quarter earnings report.

Earnings and Revenue:

Analysts are predicting an EPS reading of 77 cents per share and revenues of $1.12 billion. Wall Street will be looking to see how this quarter's numbers compare to the year-ago quarter's positive EPS of 60 cents per share on revenues of $850.4 million. We'll have to wait for Thursday to see if Celgene falls in line with analyst expectations and reports an estimated increase in both EPS and revenue from the year-ago quarter.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Quarter	Q1	Q4	Q3	Q2
EPS Estimate	$0.73	$0.67	$0.64	$0.60
EPS Actual	$0.71	$0.65	$0.65	$0.60

Stock Performance:

Shares of Celgene were trading at $61.18 as of July 22, 2011. Shares are up 3.4% year to date.

Average Stock Rating:

The average rating by analysts for Celgene is a Moderate Buy. The strength of this rating has declined slightly over the past three months.

Competitors:

Wondering how Celgene compares to rivals in the same sector? Here are a few of the company's peers.

• Bristol-Myers Squibb BMY: Hold with a $0.58 recent quarter EPS
• GlaxoSmithKline plc (ADR GSK: Hold with a $1.01 recent quarter EPS
• Cell Therapeutics (CTIC): Hold with a -$0.36 recent quarter EPS

The medical-bioengineering company's industry has seen price/earnings contraction of 9.6% during the current fiscal year.

Finally, a description of the company's main areas of operation: Celgene is a biopharmaceutical company which develops innovative therapies to treat cancer and immune-inflammatory related diseases.

Take Action:

There is your peek into Celgene's upcoming earnings numbers, including some competitors to watch around the time of the announcement. Check back in with us after the announcement for a full recap of the announcement. In the meantime, here are some links to explore today.

• To see up-to-date news on Celgene, click here
• To see other trading ideas, click here
• To see other company earnings recaps, click here